Arcus Biosciences, Inc.
https://www.arcusbio.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arcus Biosciences, Inc.
Gilead Teases Big Cancer Drug Readouts In Second Half
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire
Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet
GSK Spends Heavily On iTeos' TIGIT To Build A New IO Cornerstone
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
Gilead Made Gains In Oncology, Though Virology Remains King
Pipeline-in-a-product approaches have become popular in biopharma, and Gilead has been making significant strides.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule